MedTrace Logo

Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections

NCT03814616 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-09-30

No results posted yet for this study

Summary

This study will assess the efficacy of Pyramax administered for three-day, two-day or one day, in clearing a P. falciparum infection in asymptomatic carriers.

.

Conditions

  • Malaria,Falciparum

Interventions

DRUG

Pyronaridine tetraphosphate 180mg:artesunate 60mg

ACT

Sponsors & Collaborators

  • Medicines for Malaria Venture

    collaborator OTHER

  • Shin Poong Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Jang Sik Shin · Shin Poong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-03
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • The Gambia
  • Zambia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03814616 on ClinicalTrials.gov